News
Pharmaceutical Technology on MSN7d
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditionsSanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...
Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...
Zacks Investment Research on MSN7d
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare DiseasesSanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...
The FDA has granted orphan drug designation to rilzabrutinib for IgG4-related disease and warm autoimmune hemolytic anemia, ...
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune ...
US FDA grants orphan drug designation to Sanofi’s rilzabrutinib, an oral, reversible BTK inhibitor for two rare diseases: Paris Friday, April 4, 2025, 14:00 Hrs [IST] The US Foo ...
Sanofi's rilzabrutinib receives FDA orphan drug designation for two rare diseases. Clinical studies show meaningful response ...
Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted ...
Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback